{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:30:44Z","timestamp":1791217844596,"version":"4.1.0"},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T00:00:00Z","timestamp":1748390400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004337","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Targeting of tau pathology has long been proposed as a potential therapeutic strategy for Alzheimer's disease (AD). Semorinemab is a humanized IgG4 monoclonal antibody that binds to all known isoforms of full-length tau with high affinity and specificity. Semorinemab's safety and efficacy have been studied in two phase 2 randomized, double-blind, placebo-controlled, parallel-group clinical trials: Tauriel (prodromal-to-mild AD; NCT03289143; in which semorinemab failed to demonstrate clinical efficacy) and Lauriet (mild-to-moderate AD; NCT03828747. However, semorinemab was associated with a significant slowing in progression in a co-primary end point of cognition only in Lauriet but not in Tauriel. Proteomic profiling of CSF collected in these trials was performed to gain a better understanding of the effect of semorinemab in light of the different clinical outcomes.<\/jats:p>\n                  <jats:p>CSF was collected from a subset of patients at baseline and after 49 or 73 weeks in Tauriel and baseline and after 49 or 61 weeks in Lauriet. Samples were analysed using single-shot field asymmetric ion mobility spectrometry-data independent acquisition-mass spectrometry (FAIMS-DIA-MS) and analysed with Spectronaut and MS Stats. Proteomics results were integrated with publicly available single-nucleus brain datasets to contextualize cellular expression profiles of differentially expressed proteins.<\/jats:p>\n                  <jats:p>A novel proteomics dataset was generated using more than 250 CSF samples where more than 3500 proteins were detected. Treatment-associated proteomic signatures were defined for each clinical trial as the set of proteins significantly elevated in the treatment arm in the respective trial. Integration of the corresponding gene signatures with brain single-nucleus RNA-sequencing datasets from AD and healthy age-matched controls revealed that the Lauriet signature genes were enriched in microglia, while Tauriel signature genes were more broadly expressed across brain cell types. Furthermore, the Lauriet gene signature was significantly upregulated in microglia from AD patients compared to non-demented controls. The elevation of proteins such as CHI3L1 and GPNMB with treatment suggested an activated glial state.<\/jats:p>\n                  <jats:p>This study demonstrates the utility of CSF clinical proteomics to assess the pharmacodynamic response of semorinemab and contributes to our understanding of how an anti-tau antibody influences disease-relevant pathophysiology in AD.<\/jats:p>","DOI":"10.1093\/brain\/awaf200","type":"journal-article","created":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T07:37:37Z","timestamp":1748417857000},"page":"150-162","source":"Crossref","is-referenced-by-count":5,"title":["CSF proteomics of semorinemab Alzheimer\u2019s disease trials identifies cell-type specific signatures"],"prefix":"10.1093","volume":"149","author":[{"given":"Alyaa M","family":"Abdel-Haleem","sequence":"first","affiliation":[{"name":"Roche Informatics, F. Hoffmann-La Roche Ltd. , Mississauga, ON L5N 5M8 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Casavant","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Data and Statistical Sciences, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Teng","sequence":"additional","affiliation":[{"name":"Department of Early Clinical Development-OMNI, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Monteiro","sequence":"additional","affiliation":[{"name":"Department of Early Clinical Development-OMNI, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil J","family":"Pandya","sequence":"additional","affiliation":[{"name":"Human Pathobiology & OMNI Reverse Translation, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caspar","family":"Glock","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]},{"name":"gRED Computational Sciences, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper C","family":"Hoogenraad","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad A","family":"Friedman","sequence":"additional","affiliation":[{"name":"gRED Computational Sciences, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix L","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica G","family":"Anania","sequence":"additional","affiliation":[{"name":"Department of Translational Medicine, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloriia","family":"Novikova","sequence":"additional","affiliation":[{"name":"gRED Computational Sciences, Genentech, Inc. , South San Francisco, CA 94080 ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,28]]},"reference":[{"key":"2026010812425682600_awaf200-B1","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41572-021-00269-y","article-title":"Alzheimer disease","volume":"7","author":"Knopman","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2026010812425682600_awaf200-B2","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and efficacy of semorinemab in individuals with prodromal to mild Alzheimer disease: A randomized clinical trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol"},{"key":"2026010812425682600_awaf200-B3","doi-asserted-by":"crossref","first-page":"eabb2639","DOI":"10.1126\/scitranslmed.abb2639","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer\u2019s disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci Transl Med"},{"key":"2026010812425682600_awaf200-B4","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"key":"2026010812425682600_awaf200-B5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.cels.2016.11.006","article-title":"A multi-network approach identifies protein-specific co-expression in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"4","author":"Seyfried","year":"2017","journal-title":"Cell Syst"},{"key":"2026010812425682600_awaf200-B6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/proteomes7030030","article-title":"Network analysis of a membrane-enriched brain proteome across stages of Alzheimer\u2019s disease","volume":"7","author":"Higginbotham","year":"2019","journal-title":"Proteomes"},{"key":"2026010812425682600_awaf200-B7","doi-asserted-by":"crossref","first-page":"eaaz9360","DOI":"10.1126\/sciadv.aaz9360","article-title":"Integrated proteomics reveals brain-based cerebrospinal fluid biomarkers in asymptomatic and symptomatic Alzheimer\u2019s disease","volume":"6","author":"Higginbotham","year":"2020","journal-title":"Sci Adv"},{"key":"2026010812425682600_awaf200-B8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s43587-023-00550-7","article-title":"Cerebrospinal fluid proteomics in patients with Alzheimer\u2019s disease reveals five molecular subtypes with distinct genetic risk profiles","volume":"4","author":"Tijms","year":"2024","journal-title":"Nat Aging"},{"key":"2026010812425682600_awaf200-B9","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1002\/alz.14346","article-title":"Pharmacodynamic effects of semorinemab on plasma and CSF biomarkers of Alzheimer\u2019s disease pathophysiology","volume":"20","author":"Schauer","year":"2024","journal-title":"Alzheimers Dement"},{"key":"2026010812425682600_awaf200-B10","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1074\/mcp.RA117.000314","article-title":"Optimization of experimental parameters in data-independent mass spectrometry significantly increases depth and reproducibility of results","volume":"16","author":"Bruderer","year":"2017","journal-title":"Mol Cell Proteomics"},{"key":"2026010812425682600_awaf200-B11","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1021\/acs.jproteome.2c00122","article-title":"Biomarker candidates for tumors identified from deep-profiled plasma stem predominantly from the low abundant area","volume":"21","author":"Tognetti","year":"2022","journal-title":"J Proteome Res"},{"key":"2026010812425682600_awaf200-B12","volume-title":"WGCNA: An R package for weighted correlation network analysis","author":"Applied Research Applied Research Press","year":"2015"},{"key":"2026010812425682600_awaf200-B13","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.celrep.2017.12.066","article-title":"Diverse brain myeloid expression profiles reveal distinct microglial activation states and aspects of Alzheimer\u2019s disease not evident in mouse models","volume":"22","author":"Friedman","year":"2018","journal-title":"Cell Rep"},{"key":"2026010812425682600_awaf200-B14","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"Voom: Precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"2026010812425682600_awaf200-B15","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/bioinformatics\/btq057","article-title":"Fast and SNP-tolerant detection of complex variants and splicing in short reads","volume":"26","author":"Wu","year":"2010","journal-title":"Bioinformatics"},{"key":"2026010812425682600_awaf200-B16","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1038\/s41588-021-00894-z","article-title":"Single-nucleus chromatin accessibility and transcriptomic characterization of Alzheimer\u2019s disease","volume":"53","author":"Morabito","year":"2021","journal-title":"Nat Genet"},{"key":"2026010812425682600_awaf200-B17","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/s41592-023-01943-7","article-title":"Unsupervised removal of systematic background noise from droplet-based single-cell experiments using CellBender","volume":"20","author":"Fleming","year":"2023","journal-title":"Nat Methods"},{"key":"2026010812425682600_awaf200-B18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1895-7","article-title":"Clonally expanded CD8 T cells patrol the cerebrospinal fluid in Alzheimer\u2019s disease","volume":"577","author":"Gate","year":"2020","journal-title":"Nature"},{"key":"2026010812425682600_awaf200-B19","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1038\/s41592-019-0619-0","article-title":"Fast, sensitive and accurate integration of single-cell data with Harmony","volume":"16","author":"Korsunsky","year":"2019","journal-title":"Nat Methods"},{"key":"2026010812425682600_awaf200-B20","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: A Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2026010812425682600_awaf200-B21","doi-asserted-by":"publisher","author":"Gabitto","DOI":"10.21203\/rs.3.rs-2921860\/v1"},{"key":"2026010812425682600_awaf200-B22","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1007\/s00259-019-04399-0","article-title":"[F]GTP1 (Genentech Tau Probe 1), a radioligand for detecting neurofibrillary tangle tau pathology in Alzheimer\u2019s disease","volume":"46","author":"Sanabria Boh\u00f3rquez","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2026010812425682600_awaf200-B23","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1038\/s41591-023-02505-2","article-title":"Emerging diagnostics and therapeutics for Alzheimer disease","volume":"29","author":"Self","year":"2023","journal-title":"Nat Med"},{"key":"2026010812425682600_awaf200-B24","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s12276-020-0418-9","article-title":"New fluid biomarkers tracking non-amyloid-\u03b2 and non-tau pathology in Alzheimer\u2019s disease","volume":"52","author":"Park","year":"2020","journal-title":"Exp Mol Med"},{"key":"2026010812425682600_awaf200-B25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4103\/bc.BC_3_18","article-title":"Cerebrospinal fluid circulation: What do we know and how do we know it?","volume":"4","author":"Khasawneh","year":"2018","journal-title":"Brain Circ"},{"key":"2026010812425682600_awaf200-B26","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1007\/s00401-021-02372-6","article-title":"Diverse human astrocyte and microglial transcriptional responses to Alzheimer\u2019s pathology","volume":"143","author":"Smith","year":"2022","journal-title":"Acta Neuropathol"},{"key":"2026010812425682600_awaf200-B27","doi-asserted-by":"crossref","first-page":"111189","DOI":"10.1016\/j.celrep.2022.111189","article-title":"Disease-associated oligodendrocyte responses across neurodegenerative diseases","volume":"40","author":"Pandey","year":"2022","journal-title":"Cell Rep"},{"key":"2026010812425682600_awaf200-B28","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-022-00702-0","article-title":"The challenges of anti-tau therapeutics in Alzheimer disease","volume":"18","author":"Panza","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"2026010812425682600_awaf200-B29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1097\/NEN.0b013e31825018f7","article-title":"Correlation of Alzheimer disease neuropathologic changes with cognitive status: A review of the literature","volume":"71","author":"Nelson","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"key":"2026010812425682600_awaf200-B30","doi-asserted-by":"crossref","first-page":"e9356","DOI":"10.15252\/msb.20199356","article-title":"Proteome profiling in cerebrospinal fluid reveals novel biomarkers of Alzheimer\u2019s disease","volume":"16","author":"Bader","year":"2020","journal-title":"Mol Syst Biol"},{"key":"2026010812425682600_awaf200-B31","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1038\/s41467-023-40208-x","article-title":"Compilation of reported protein changes in the brain in Alzheimer\u2019s disease","volume":"14","author":"Askenazi","year":"2023","journal-title":"Nat Commun"}],"container-title":["Brain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/brain\/advance-article-pdf\/doi\/10.1093\/brain\/awaf200\/63393825\/awaf200.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/1\/150\/63393825\/awaf200.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/brain\/article-pdf\/149\/1\/150\/63393825\/awaf200.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T17:43:10Z","timestamp":1767894190000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/brain\/article\/149\/1\/150\/8152362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,28]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,5,28]]},"published-print":{"date-parts":[[2026,1,8]]}},"URL":"https:\/\/doi.org\/10.1093\/brain\/awaf200","relation":{},"ISSN":["0006-8950","1460-2156"],"issn-type":[{"value":"0006-8950","type":"print"},{"value":"1460-2156","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,1]]},"published":{"date-parts":[[2025,5,28]]}}}